Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

NCT04706416 is registered in ClinicalTrials.gov with Quantinosis.ai LLC as lead sponsor.

NCT NCT04706416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04706416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Lead sponsor
Quantinosis.ai LLC
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2020
Completion date
January 15, 2021
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid19